A Phase II Pilot Trial of CHOP Followed By Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies

J Kelly;G Salles;B Goldman;RI Fisher;O Casasnovas;O Press;DG Maloney;P Soubeyran;L Rimsza;M Leblanc;H Tilly;J Friedberg Journal of Clinical Oncology May 1;33(13):1482-1490

PMid: PMID25823738 | PMC number: PMC4404425

Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular lymphoma

M Mir;MJ Mauer;SC Ziesmer;S Slager;T Habermann;W Macon;BK Link;S Syrbu;T Witzig;J Friedberg;O Press;M Leblanc;J Cerhan;A Novak;S Ansell Blood Feb 5;125(6):992-998

PMid: PMID25422100 | PMC number: PMC4319239

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

D Persky;D Dornan;B Goldman;R Braziel;R Fisher;M LeBlanc;DG Maloney;OW Press;TP Miller;L Rimsza Haematologica 97(6):937-942

PMid: PMID22271896 | PMC number: PMC3366663

Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation and replication in SWOG and LYSA

JL Kelly;G Salles;B Goldman;R Fisher;O Casasnovas;O Press;D Maloney;P Soubeyran;L Rimsza;M Leblanc;H Tilly;J Friedberg Blood 120(21):abst.2712; American Society of Hematology, poster;

Prognostic value of regulatory T-cells, lymphoma associated macrophages and Mum-11 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study [PMC2875547; PMID19875761]

JW Sweetenham;B Goldman;M LeBlanc;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;LM Rimsza;ED Hsi Annals of Oncology 21(6):1196-1202;

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

DO Persky;D Dornan;B Goldman;M LeBlanc;RM Braziel;RI Fisher;D Maloney;T Miller;OW Press;LM Rimsza Blood 114:abst.#111 (ASH Annual Meeting, oral presentation)

Non-hodgkins lymphoma

R Fisher;P Mauch;J Friedberg;L Rimsza In Cancer: Principles and Practice of Oncology, 8th edition, Lippincott, Williams & Wilkins, Baltimore, MD, pp 2098-2158, 2008

MUM1 expression in follicular lymphoma is a poor prognostic marker in patients treated with immunochemotherapy (SWOG 9800/9911) but not chemotherapy alone (SWOG 8809): A Southwest Oncology Group correlative science study

ED Hsi;B Goldman;LM Rimsza;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;JW Sweetenham Blood 112(11):146, abst. 376

Numbers of lymphoma associated macrophages (LAMS) and regulatory T-cells (Tregs) in follicular lymphoma (FL) patients (pts) treated with and without monoclonal antibody (MoAb)-containing therapy do not correlate with overall survival (OS): a study from the Southwest Oncology Group (SWOG)

JW Sweetenham;E Hsi;B Goldman;M LeBlanc;RR Tubbs;JR Cook;OW Press;RI Fisher;LM Rimsza Blood 110(11):#2602

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 Tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow up of Southwest Oncology Group protocol S9911

OW Press;JM Unger;RM Braziel;DG Maloney;TP Miller;M LeBlanc;RI Fisher Journal of Clinical Oncology 24(25):4143-4149

An update of a phase II trial of CHOP followed by tositumomab/iodine I-131 tositumomab (Bexxar) for front-line treatment of advanced stage, follicular lymphoma: Southwest Oncology Group Protocol 9911

OW Press;J Unger;D Maloney;RM Braziel;M LeBlanc;T Grogan;TP Miller;RI Fisher Blood (ASH Annual Meeting Abstracts) 106(11): #352

New treatment options have changed the survival of patients with follicular lymphoma

RI Fisher;M LeBlanc;OW Press;DG Maloney;JM Unger;TP Miller Journal of Clinical Oncology 23(33):8447-8452

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular Non-Hodgkin's Lymphoma. Southwest Oncology Group Protocol S9911

OW Press;JM Unger;RM Braziel;DG Maloney;TP Miller;M LeBlanc;ER Gaynor;SE Rivkin;RI Fisher Blood 102(5):1606-1612

CHOP followed by tositumomab/iodine I 131 tositumomab (Bexxar) for treatment of newly diagnosed follicular non-Hodgkin's Lymphomas: a phase II trial of the Southwest Oncology Group (S9911)

OW Press;JM Unger;RM Braziel;DG Maloney;TP Miller;M LeBlanc;RI Fisher Blood 102(11):(#90)

A phase III trial of CHOP followed by Bexxar (tositumomab and Iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911)

OW Press;JM Unger;RM Braziel;DG Maloney;ML LeBlanc;TM Grogan;TP Miller;RI Fisher Blood 98(11):843a-844a(#3504)